Saturday, January 8, 2011

Mesothelioma Information News - Bristol-Myers Squibb Agrees to Cancer Drug Overcharge Settlement

Bristol-Myers Squibb (BMS), has agreed to pay $19 million to patients and insurance companies for the overcharging of certain cancer drugs.

These drugs were among those used for treating Mesothelioma and many other types of cancer. One of these drugs, Blenoxane, is often used to treat the buildup of fluid between the chest wall and the lining of the lungs. This condition commonly occurs with pleural mesothelioma patients.

Details of the settlement indicate that the reported average wholesale prices reported by BMS, were inflated. BMS has denied fault, but has agreed to settle rather than incur the expense of lengthy litigation.

For more information about this settlement, visit